eligibility_summary
Include: Adults 18–75, ECOG 0–1, ≥3‑mo survival, inoperable advanced/metastatic/recurrent NSCLC after standard therapy failure, ≥1 measurable lesion, contraception (women not pregnant/lactating). Exclude: recent other cancer, unresolved >G1 AEs, surgery/RT or unhealed wounds, ILD/pneumonitis/TB, thrombosis, severe/uncontrolled illness, active CNS mets/meningitis, effusions with drainage, bone events, allergy to mAbs/study meds, recent anticancer/trial/TCM or live vaccine.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2 trial in HER2-abnormal NSCLC testing: 1) TQB2102, a HER2-targeted antibody–drug conjugate (humanized anti-HER2 mAb + enzyme-cleavable linker + topoisomerase I inhibitor payload). Mechanism: binds HER2 on tumor cells (ERBB2 pathway), internalizes, linker cleavage releases topo I inhibitor to cause DNA damage and cell death (with possible bystander effect). 2) TQB2102 combined with benmelstobart, a PD‑L1–blocking monoclonal antibody (checkpoint inhibitor). Targets/pathways: HER2/ERBB2 on tumor cells, DNA replication via topo I, and the PD‑1/PD‑L1 axis to activate cytotoxic T cells in the tumor microenvironment.